Sam Lanyon
Président chez LUMOS DIAGNOSTICS HOLDINGS LIMITED
Profil
Sam Lanyon is the founder.
He founded Planet Innovation Pty Ltd.
in 2009 and holds the title of Executive Director.
Currently, Mr. Lanyon is the Executive Chairman at Lumos Diagnostics, Lumos Diagnostics Holdings Ltd., and Director at Visus Therapeutics, Inc. In the past, he worked as a Director at Waterwerx Pty Ltd.
and Zen Ecosystems.
Mr. Lanyon's education includes an undergraduate degree from the University of Melbourne.
Postes actifs de Sam Lanyon
| Sociétés | Poste | Début |
|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Président | 01/01/2019 |
Visus Therapeutics, Inc.
 Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Lumos Diagnostics
 Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Président | - |
Planet Innovation Pty Ltd.
 Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Fondateur | 01/01/2009 |
Anciens postes connus de Sam Lanyon
| Sociétés | Poste | Fin |
|---|---|---|
| Zen Ecosystems | Directeur/Membre du Conseil | - |
| Waterwerx Pty Ltd. | Directeur/Membre du Conseil | - |
Formation de Sam Lanyon
| University of Melbourne | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
| Waterwerx Pty Ltd. | |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Health Technology |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
| Zen Ecosystems |
